Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Study of Apabetalone in Covid Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provide informed consent before participation in the study.~2. Aged ≥18 years~3. Hospital admission with symptoms suggestive of COVID-19 infection~4. Ten days or less since the onset of symptoms~5. Virological confirmation of SARS-CoV2 infection by reverse transcriptase PCR (RT- PCR) according to Center for Disease Control and Prevention (CDC) guidelines within the previous 72 hours~6. Subjects showing bilateral pulmonary infiltrates on chest imaging~7. Saturation of oxygen (SpO2) by pulse oximetry \<94% on room air at sea level.~8. Female subjects must meet one of the following:~   * If of childbearing potential, female subjects must have a negative urine pregnancy test at screening and must also be willing to practice total abstinence or to use an approved (non-hormonal) form of birth-control throughout the study treatment phase and up to 28 days after the last study drug dose if randomized to apabetalone. -OR-~  * Meet at least one of the following criteria:~  * Be postmenopausal, defined as having been amenorrheic for at least 2 years~  * Have had a hysterectomy or a bilateral oophorectomy~Exclusion Criteria:~1. Subjects with SpO2 \>94% on room air using pulse oximetry and without bilateral infiltrates on chest imaging~2. Subjects requiring mechanical ventilation or extracorporeal membrane oxygenation~3. Patients with Stage 5 CKD receiving renal replacement therapy with either hemodialysis or peritoneal dialysis, renal transplant or with eGFR \<15 mL/min/1.73 m2.~4. Patients with prior transplantations of organs or bone marrow.~5. Patients with unstable cardiac condition including heart attack, stroke, uncontrolled atrial fibrillation or a major cardiac procedure within 3 months as assessed by the investigator.~6. New York Heart Association Class IV congestive heart failure.~7. Evidence of cirrhosis from liver imaging or biopsy, a history of hepatic encephalopathy, esophageal or gastric varices, active hepatitis, or prior porta-caval shunt procedure.~8. ALT or AST \>5 x ULN on admission laboratory assessment.~9. Total bilirubin \>2 x ULN on admission laboratory assessment.~10. Have received any live attenuated vaccine within 90 days at dosing.~11. Known human immunodeficiency virus positive patients.~12. Chronic use of oxygen therapy at home~13. Have participated in a clinical study and received any investigational medication within the last 30 days preceding Visit 1 (Screening).~14. Subjects whose safety may be compromised by study participation~15. Are not, in the opinion of the investigator, able or willing to comply with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: OTHER): All subjects will receive SOC during their hospital admission. This will include daily vital signs, WHO Ordinal Scale assessment and adverse events. On Days 3, 5, 7 and 11, hematology, chemistry, oropharyngeal or nasopharyngeal swabs for Covid-19 viral levels and biomarkers samples the same as at the screening visit will be taken if the patient remains in hospital.
- Standard of Care plus apabetalone (Type: EXPERIMENTAL): All subjects will receive SOC during their hospital admission. This will include daily vital signs, WHO Ordinal Scale assessment and adverse events. On Days 3, 5, 7 and 11, hematology, chemistry, oropharyngeal or nasopharyngeal swabs for Covid-19 viral levels and biomarkers samples the same as at the screening visit will be taken if the patient remains in hospital. For the apabetalone cohort, treatment will be administered BID with meals.

Based on this trial design, predict the completion outcome and termination type (if applicable).